WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2008095820) (INDOL-4-YL)- OR (INDOL-5-YL)-PIPERAZINYLMETHANONE DERIVATIVES FOR THE TREATMENT OF OBESITY
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2008/095820    International Application No.:    PCT/EP2008/050996
Publication Date: 14.08.2008 International Filing Date: 29.01.2008
IPC:
C07D 209/08 (2006.01), C07D 235/06 (2006.01), A61K 31/496 (2006.01), A61P 3/00 (2006.01)
Applicants: F. HOFFMANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse 124, CH-4070 Basel (CH) (For All Designated States Except US).
NETTEKOVEN, Matthias [DE/DE]; (DE) (For US Only).
ROCHE, Olivier [FR/FR]; (FR) (For US Only)
Inventors: NETTEKOVEN, Matthias; (DE).
ROCHE, Olivier; (FR)
Agent: KLOSTERMEYER, Doerte; Grenzacherstrasse 124, CH-4070 Basel (CH)
Priority Data:
07101870.9 07.02.2007 EP
Title (EN) (INDOL-4-YL)- OR (INDOL-5-YL)-PIPERAZINYLMETHANONE DERIVATIVES FOR THE TREATMENT OF OBESITY
(FR) DÉRIVÉS D'(INDOL-4-YL)- OU D'(INDOL-5-YL)-PIPÉRAZINYLMÉTHANONE DESTINÉS AU TRAITEMENT DE L'OBÉSITÉ
Abstract: front page image
(EN)The present invention relates to compounds of Formula (I), wherein one of R1 and R2 is hydrogen and the other one is, and wherein A and R1 to R4 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.
(FR)L'invention concerne des composés de formule (I), dans laquelle l'un de R1 et R2 représente un hydrogène et l'autre représente (II), dans cette formule A et R1 à R4 sont tels que définis dans la description et les revendications. L'invention concerne également des sels de ces composés pharmaceutiquement acceptable. Ces composés sont utiles dans le traitement et/ou la prévention de maladies associées à la modulation des récepteur H3.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)